"シオノギ製薬" の関連情報検索結果
Shionogi to Announce Personnel Reassignment| 塩野義製薬 - Shionogi
Notice of Head Office Relocation| 塩野義製薬 - Shionogi
Nxera Pharma Enters New Commercial Partnership with Shionogi for QUVIVIQ™ in Japan - GlobeNewswire
Nxera Pharma Enters New Commercial Partnership with Shionogi for QUVIVIQ™ in Japan GlobeNewswire
Is Weakness In Shionogi & Co., Ltd. (TSE:4507) Stock A Sign That The Market Could be Wrong Given ...
Is Weakness In Shionogi & Co., Ltd. (TSE:4507) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects? Simply Wall St
Nxera Pharma Partners with Shionogi for Quviviq Distribution in Japan - Sleep Review
Nxera Pharma Partners with Shionogi for Quviviq Distribution in Japan Sleep Review
Japan's Shionogi says COVID treatment did not meet endpoint in late-stage trial - Reuters
Japan's Shionogi says COVID treatment did not meet endpoint in late-stage trial Reuters
Shionogi presents largest global real-world evidence study of cefiderocol - The Pharma Letter
Shionogi presents largest global real-world evidence study of cefiderocol The Pharma Letter
IDWeek 2024: Shionogi Presents Largest Global Real-World Evidence Study of Cefiderocol Demonstrat...
Clinical Report: Shionogi mulls next steps after underwhelming obesity readout - BioCentury
Clinical Report: Shionogi mulls next steps after underwhelming obesity readout BioCentury
Shionogi Continues Global Commitment to Advances in Infectious Disease with Key Data Presentation...
Will the Next Oral COVID-19 Drug Come from Japan? - JAPAN Forward
Will the Next Oral COVID-19 Drug Come from Japan? JAPAN Forward
The public wants Medicare to cover obesity drugs - STAT
After FTC stalled Sanofi deal, Shionogi secures Maze's Pompe disease drug for $150M - Fierce Biotech
After FTC stalled Sanofi deal, Shionogi secures Maze's Pompe disease drug for $150M Fierce Biotech
David Benadon| 塩野義製薬 - Shionogi
David Benadon| 塩野義製薬 Shionogi
Shionogi & Co., Ltd. and Maze Therapeutics, Inc. Announce Exclusive Worldwide License Agreement f...
Merging with the US biotech venture Qpex: A chronicle of striving for the integration process aim...
SHIONOGI’s Commitment to Antibiotics: Aiming for an Ideal Collaboration between Industry, Governm...
Recognized with the Double A List for Leadership in Corporate Transparency and Performance on Cli...
Leveraging Real-world Data and Artificial Intelligence: The Story Behind the Outstanding Leadersh...
Researchers on One Health and the Proper Use of Medications: Behind the Scenes of Rare Species Co...
Cilcare and Shionogi Announce Option Agreement for Hearing Disorder Treatment - The Hearing Review
Cilcare and Shionogi Announce Option Agreement for Hearing Disorder Treatment The Hearing Review
Shionogi's antiviral comes up short in global COVID-19 trial - FiercePharma
Shionogi's antiviral comes up short in global COVID-19 trial FiercePharma
Shionogi Provides Updates on Zatolmilast, an Investigational Drug for Fragile X Syndrome, Includi...
Nxera Pharma and Shionogi partner on Quviviq | Pharmaceutical | The Pharmaletter - The Pharma Letter
Nxera Pharma and Shionogi partner on Quviviq | Pharmaceutical | The Pharmaletter The Pharma Letter
Comparative Effectiveness of Baloxavir Marboxil and Oseltamivir Treatment in Reducing Household T...
Comparative Effectiveness of Baloxavir Marboxil and Oseltamivir Treatment in Reducing Household Transmission of Influenza: A Post Hoc Analysis of the BLOCKSTONE Trial Wiley Online Library
Shionogi files NDA in Japan for zuranolone in MDD - The Pharma Letter
Shionogi files NDA in Japan for zuranolone in MDD The Pharma Letter
Qpex Biopharma, a Shionogi Group Company, Receives an Additional $10M Award by BARDA as Part of Q...
Dialogue 2021|シオノギ製薬(塩野義製薬) - Shionogi
Dialogue 2021|シオノギ製薬(塩野義製薬) Shionogi
Shionogi’s MGAT2 inhibitor improves metabolism in obesity models - BioWorld Online
Shionogi’s MGAT2 inhibitor improves metabolism in obesity models BioWorld Online
Japan's Shionogi seeks China approval for superbug-fighting antibiotic - Nikkei Asia
Japan's Shionogi seeks China approval for superbug-fighting antibiotic Nikkei Asia
Nxera Pharma Partners with Shionogi on Insomnia Drug - TipRanks
Nxera Pharma Partners with Shionogi on Insomnia Drug TipRanks
Shionogi’s COVID-19 drug misses endpoint in global phase III - BioWorld Online
Shionogi’s COVID-19 drug misses endpoint in global phase III BioWorld Online
Shionogi Expands Global Infectious Disease and Antimicrobial Research Operations to U.S. to Addre...
Shionogi presents new GLP-1R agonists for obesity and diabetes - BioWorld Online
Shionogi presents new GLP-1R agonists for obesity and diabetes BioWorld Online
Japan's Shionogi eyes early 2025 for U.S. release of COVID pill - Nikkei Asia
Japan's Shionogi eyes early 2025 for U.S. release of COVID pill Nikkei Asia
Digital therapeutics player Akili weighs options, cuts workforce in half - Axios
Digital therapeutics player Akili weighs options, cuts workforce in half Axios
Shionogi's COVID Drug Stumbles, Yet Eyes Future Success - Finimize
Shionogi's COVID Drug Stumbles, Yet Eyes Future Success Finimize
Shionogi commences Phase III monovalent Covid-19 vaccine trial - Clinical Trials Arena
Shionogi commences Phase III monovalent Covid-19 vaccine trial Clinical Trials Arena
Japan's Shionogi announces $150 M deal to develop first oral therapy for Pompe Disease - BSA bureau
Japan's Shionogi announces $150 M deal to develop first oral therapy for Pompe Disease BSA bureau
Regulators caused breakup of potential $750 million drug deal — now they've blessed company's lat...
Regulators caused breakup of potential $750 million drug deal — now they've blessed company's latest move The Business Journals
New Antivirals for Today's COVID-19: Ensitrelvir and Beyond - Infectious Disease Special Edition
New Antivirals for Today's COVID-19: Ensitrelvir and Beyond Infectious Disease Special Edition
Shionogi’s oral COVID-19 antiviral wins full approval in Japan - BioWorld Online
Shionogi’s oral COVID-19 antiviral wins full approval in Japan BioWorld Online
Shionogi, Fronteo developing AI diagnostic support models for dementia, depression - BioWorld Online
Shionogi, Fronteo developing AI diagnostic support models for dementia, depression BioWorld Online
Shionogi Announces New Phase 3 Data Showing Early Resolution of Many Common COVID-19 Symptoms in ...
Shionogi Announces New Phase 3 Data Showing Early Resolution of Many Common COVID-19 Symptoms in JAMA Network Open Business Wire
Keiko Tone - Shionogi - Board Member - The Association of the British Pharmaceutical Industry
Keiko Tone - Shionogi - Board Member The Association of the British Pharmaceutical Industry
Advancing Malaria Research: Nagasaki University and Shionogi Extend Industry-Academia Partnership...
Advancing Malaria Research: Nagasaki University and Shionogi Extend Industry-Academia Partnership nagasaki-u.ac.jp
Generative AI turns conference attendees into infectious disease warriors - MM+M Online
Generative AI turns conference attendees into infectious disease warriors MM+M Online
NIH trial to evaluate Shionogi antiviral in adults hospitalized with COVID-19 - National Institut...
NIH trial to evaluate Shionogi antiviral in adults hospitalized with COVID-19 National Institutes of Health (NIH) (.gov)
Taiwan approves Japan-based Shionogi's influenza drug for paediatric use - BSA bureau
Taiwan approves Japan-based Shionogi's influenza drug for paediatric use BSA bureau
Japan's Shionogi inks €400 M deal with French firm Cilcare to address hearing loss - BSA bureau
Japan's Shionogi inks €400 M deal with French firm Cilcare to address hearing loss BSA bureau
Roche touts positive Phase III results with Xofluza - The Pharma Letter
Roche touts positive Phase III results with Xofluza The Pharma Letter
European Commission offers hope for misunderstood intellectual disability and autism condition, F...
European Commission offers hope for misunderstood intellectual disability and autism condition, FXS OutSourcing-Pharma.com
Address the problem of antimicrobial resistance (AMR) | Sustainability | Shionogi & Co., Ltd. - S...
Address the problem of antimicrobial resistance (AMR) | Sustainability | Shionogi & Co., Ltd. Shionogi
Launch of the Third Phase for the Mother to Mother SHIONOGI Project New Activities to Support Mat...
Annual Report / Integrated Report / Environment Report | IR Library | Shionogi & Co., Ltd. - Shio...
Annual Report / Integrated Report / Environment Report | IR Library | Shionogi & Co., Ltd. Shionogi
Shionogi Announces Agreement With SOBI - European Pharmaceutical Manufacturer
Shionogi Announces Agreement With SOBI European Pharmaceutical Manufacturer
Margaret Borys - Shionogi
Margaret Borys Shionogi
“Defy Dementia with Sound.” Pixie Dust Technologies, Shionogi and Shionogi Healthcare create Gamm...
Medium-Term Business Plan STS2030 Revision(FY2023 – FY2030) | Business Strategy | Shionogi & Co...
Shionogi and Osaka University unveils a new joint research lab to review anti-COVID-19 drug - BSA...
Shionogi and Osaka University unveils a new joint research lab to review anti-COVID-19 drug BSA bureau
Message from Top Management - Shionogi
Message from Top Management Shionogi
Partnering to Bring Meaningful Science to Patients - Shionogi
Shionogi Certified as the First Eco-First Company in the Pharmaceutical Industry of Environmental...
Mother to Mother SHIONOGI Project - Shionogi
Mother to Mother SHIONOGI Project Shionogi
New data from Japan shows early resolution of common Covid-19 symptoms - BioPharma-Reporter.com
New data from Japan shows early resolution of common Covid-19 symptoms BioPharma-Reporter.com
History - Shionogi
History Shionogi
Climate Change | Environment | Shionogi & Co., Ltd. - Shionogi
Climate Change | Environment | Shionogi & Co., Ltd. Shionogi
Tadashi Hara - Shionogi
Tadashi Hara Shionogi
What we stand for: Takeki Uehara - Shionogi
What we stand for: Takeki Uehara Shionogi
Japan’s Nagasaki University and Shionogi extend industry-academia partnership to eliminate malari...
Japan’s Nagasaki University and Shionogi extend industry-academia partnership to eliminate malaria BSA bureau
Nathan McCutcheon - Shionogi
Nathan McCutcheon Shionogi
Taiwan FDA approves Shionogi's FETROJA for treating complicated urinary tract infections - BSA bu...
Taiwan FDA approves Shionogi's FETROJA for treating complicated urinary tract infections BSA bureau
“Gamma wave sound weather forecast” using “gamma wave sound” jointly developed by Pixie Dust Tech...
“Gamma wave sound weather forecast” using “gamma wave sound” jointly developed by Pixie Dust Technologies and Shionogi & Co., starts regular broadcasting on Japan’s first radio program, Bunka Broadcasting Pixie Dust Technologies, Inc.
A&O advises Shionogi on its strategic joint venture with Apnimed for the development of therapies...
Shionogi expresses its support for the recommendations of Task Force on Climate-related Financial...
Shionogi has been Selected as One of the Excellent Integrated Reports by the GPIF's Domestic Equi...
Diversity and inclusion | Attractive work environment | Shionogi & Co., Ltd. - Shionogi
Diversity and inclusion | Attractive work environment | Shionogi & Co., Ltd. Shionogi
Financial Highlights | Investors | Shionogi & Co., Ltd. - Shionogi
Financial Highlights | Investors | Shionogi & Co., Ltd. Shionogi
Shionogi Wins Second Prize in NIKKEI Integrated Report Award 2022 - Shionogi
Shionogi Wins Second Prize in NIKKEI Integrated Report Award 2022 Shionogi
Research Topics - Shionogi
Research Topics Shionogi
Japan's Shionogi says COVID-19 pill shows rapid clearance of virus - Reuters
Japan's Shionogi says COVID-19 pill shows rapid clearance of virus Reuters
Antimicrobial resistance: Shionogi advocates policy change to address the public health threat - ...
Antimicrobial resistance: Shionogi advocates policy change to address the public health threat Nature.com
Improving access to healthcare services in developing countries - Shionogi
Improving access to healthcare services in developing countries Shionogi
Staying ahead of antimicrobial resistance - Nature.com
Staying ahead of antimicrobial resistance Nature.com
Shionogi Buys Qpex Biopharma for $140M, Expands Antimicrobial Pipeline - BioSpace
Shionogi Buys Qpex Biopharma for $140M, Expands Antimicrobial Pipeline BioSpace
WADA and Shionogi pharmaceutical company sign MOU formalizing collaboration to protect clean spor...
WADA and Shionogi pharmaceutical company sign MOU formalizing collaboration to protect clean sport WADA
Initiatives to support people with neurodevelopmental disorders | Society | Shionogi & Co., Ltd. ...
Initiatives to support people with neurodevelopmental disorders | Society | Shionogi & Co., Ltd. Shionogi
Shionogi splashes $100M on F2G's rare fungal disease drug to unlock new class of medicine - Fierc...
Shionogi splashes $100M on F2G's rare fungal disease drug to unlock new class of medicine Fierce Biotech
Fierce Pharma Asia—Shionogi's Qpex buy; Takeda's rare disease win; AbbVie's patent suit against B...
Fierce Pharma Asia—Shionogi's Qpex buy; Takeda's rare disease win; AbbVie's patent suit against BeiGene FiercePharma
Shionogi Falls After a Panel Postpones Decision on Covid Pill - Bloomberg
Shionogi Falls After a Panel Postpones Decision on Covid Pill Bloomberg
UK to Roll Out Drugs From Pfizer, Shionogi to Fight Superbugs - Bloomberg
UK to Roll Out Drugs From Pfizer, Shionogi to Fight Superbugs Bloomberg
Development of a Manufacturing Process toward the Convergent Synthesis of the COVID-19 Antiviral ...
Development of a Manufacturing Process toward the Convergent Synthesis of the COVID-19 Antiviral Ensitrelvir ACS Publications
Japan's Shionogi starts phase III clinical trial in Vietnam for Covid-19 vaccine - Reuters
Japan's Shionogi starts phase III clinical trial in Vietnam for Covid-19 vaccine Reuters
COVID pill is first to cut short positive-test time after infection - Nature.com
COVID pill is first to cut short positive-test time after infection Nature.com
Shionogi’s Covid-19 Pill Ready to Move to Final Trial Phase - Bloomberg
Shionogi’s Covid-19 Pill Ready to Move to Final Trial Phase Bloomberg
Japanese drugmaker urges G7 to fix infectious diseases market - Financial Times
Japanese drugmaker urges G7 to fix infectious diseases market Financial Times
Shionogi’s growing anti-infectives portfolio - Nature.com
Shionogi’s growing anti-infectives portfolio Nature.com
Eisai, BeiGene, Shionogi—Fierce Pharma Asia - FiercePharma
Eisai, BeiGene, Shionogi—Fierce Pharma Asia FiercePharma
In global access push, Orchid Pharma gains license to manufacture the antibiotic cefiderocol - Fi...
In global access push, Orchid Pharma gains license to manufacture the antibiotic cefiderocol FiercePharma
Americans Don’t Get to Have the Best New COVID Drug - The Atlantic
Americans Don’t Get to Have the Best New COVID Drug The Atlantic